Previous 10 | Next 10 |
Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi Proceeds Used to Repay Debt Principal with Oxford Finance PR Newswire LA JOLLA, Calif., Oct. 13, 2020 LA JOLLA, Calif. , Oct. 13, 2020 /PRNewswire/ -- Reg...
The following slide deck was published by Regulus Therapeutics Inc. in conjunction with this Read more ...
LA JOLLA, Calif. , Sept. 11, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Exe...
LA JOLLA, Calif. , Sept. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Exec...
Regulus Therapeutics ( RGLS -2.6% ) amends agreement with Sanofi ( SNY +0.2% ) relating to the the receipt of potential milestones under the out-licensing of global exclusive rights to develop and commercialize miR-21 compounds. More news on: Regulus Therapeutics Inc., ...
LA JOLLA, Calif. , Aug. 31, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that pursuant to an amendment of its term loan agre...
Regulus Therapeutics (NASDAQ: RGLS ) : Q2 GAAP EPS of -$0.23 misses by $0.12 . More news on: Regulus Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LA JOLLA, Calif. , Aug. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the ...
LA JOLLA, Calif. , Aug. 6, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive ...
LA JOLLA, Calif. , Aug. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Denis ...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...